SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

Please provide your email address to receive an email when new articles are posted on . Ninety-five percent of patients achieved treatment success at 8 weeks after administration of Rebyota via ...

Bethesda, MD (Feb. 21, 2024) — In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological ...

Minnie Hatch, 29, from Salt Lake City, had painful stomach cramps, and other symptoms for months before finding out she had Clostridioides difficile, or C. diff. These bacteria can grow out of control ...

4. However, researchers found fecal microbiota transplantation via colonoscopy to be most cost-effective in treating recurrent C. diff in 4 out of 4 studies. “The cost-effectiveness of fidaxomicin ...

C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive system. It is one of the most common causes of diarrhea linked to ...

SEATTLE – Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, and kills up to 30,000. It is a leading cause of ...

The pathogen C. diff -- the most common cause of health care-associated infectious diarrhea -- can use a compound that kills the human gut's resident microbes to survive and grow, giving it a ...